Int J Pathol Clin Res ISSN: 2469-5807

• Abstract
• Keyword
• Introduction
• Biology and Function of Calprotectin
• Calprotectin, Endothelial Dysfunction and Atherosclerosis
• Calprotectin in Diabetes Mellitus
• Conclusion
• Conflict of Interest
• Acknowledgement
• References

Download PDF
    

International Journal of Pathology and Clinical Research

Consultant of Cardiology Unit, Internal Medicine Department, State Medical University, Ukraine

Abstract

The low-intense inflammation is discussed as a one of the clue of various faces of pathogenesis of diabetes mellitus (DM) including insulin resistance, mitochondrial dysfunction, lipotoxity, oxidation injury that contributed in cardiovascular (CV) disease and clinical outcomes. However, there are a lot of candidates for on early biological marker that could stratify DM patients at CV risk. The myeloid-related protein 8/14 known as calprotectin is a heterodimeric complex of calcium-binding proteins, which is predominantly expressed in activated human neutrophils, monocytes, adipocytes, and innate immunity cells including macrophages, but not in normal tissue macrophages. Calprotectin may activate of Toll-like receptor 4 as innate amplifier of infection, autoimmunity, and cancer that attenuates some extracellular functions, i.e. antimicrobial, cytostatic, and chemotactic activities. Therefore, calprotectin activates of NADPH oxidase, induces apoptotic caspase-9 and caspase-3 activation, DNA fragmentation, and membrane phosphatidylserine exposure, and increases the activation of nuclear factor-κB by promoting the nuclear translocation of p65 in target cells. Recent clinical studies have shown that calprotectin was found as a marker for activation of granulocytes, mononuclear phagocytes and immune cells that play a pivotal role in tissue damage, it could link important molecular pathological mechanisms of inflammation contributing to endothelial damage. The aim of the review is summarize of knowledge regarding predictive value of calprotectin as surrogate biomarker of CV events in DM patients.

Keyword

Calprotectin, Inflammation, Diabetes mellitus, Cardiovascular disease

Introduction

Diabetes mellitus (DM) remains a one of leading causes of cardiovascular (CV) disease development [1]. It is well known that type 1 and type 2 DM increase CV morbidity and mortality globally through their complications and negative effects on nature evolution of CV disease [2]. Despite both types of DM have different characteristics affected genetics, aged of populations, sex- and family-related particularities, pathophysiology, clinical presentation, complications, prognosis, and require distinguished management [3-6], low-intense inflammation is discussed as a one of the clue of various faces of pathogenesis of DM including insulin resistance, mitochondrial dysfunction, lipotoxicity, oxidation injury, that contributed in CV disease and clinical outcomes [7-9]. Interestingly that insulin resistance and inflammation do not develop at the same time in all tissues in DM [1,10]. In this context, an adipose tissue is considered a one of the tissues where inflammation is established earlier during aging and prior insulin resistance [10,11]. There are evidences regarding a strong link between abundant secretions of several spectrum pro-inflammatory cytokines i.e. tumor necrosis factor (TNF), interleukin (IL)-1, IL-6, monocyte chemoattractant protein 1, and vascular cell adhesion molecule-1 by macrophage infiltrated adipose tissue and insulin resistance [11,12]. Although an exaggerated inflammatory response in DM is associated with CV disease development and other complications related to nature evolution of DM, the "ideal" surrogate biomarker that might predict CV disease and would therefore be useful in routine clinical use is still not identified [10-12]. The one of candidates on early biological marker that could stratify DM patients at CV risk is inflammatory-related myeloid-related protein complex calprotectin. Recent animal and clinical studies have been shown that calprotectin concentration could represent an independent risk factor of type 2 DM, and a potential surrogate marker of inflammation and endothelial dysfunction in both types of DM [13,14]. The aim of the review is to summarize of knowledge regarding predictive value of calprotectin as surrogate biomarker of CV events in DM patients.

Biology and Function of Calprotectin

Calprotectin is calcium and zinc binding heterocomplex protein (known as Myeloid-Related Protein (MRP) complex 8/14, S100A8/A9), which is comprised of two intracellular calcium-binding proteins named S100A8 (MRP8), and S100A9 (also referred to as S100A8/A9 MRP14) [15,16]. Both S100 proteins are abundant in cytosol of phagocytes and exert diverse effects with respect to its intracellular versus extracellular actions as well as its expressions in various cell types. They play critical roles in numerous cellular processes such as motility and danger signalling by interacting and modulating the activity of target proteins.

The abundant expression of calprotectin (MRP8/14) in activated human neutrophils, monocytes, adipocytes, and innate immunity cells including macrophages, indicate an exclusive role in immunity [17-19]. The expression of this factor is down-regulated during maturation to macrophages and, however, calprotectin is absent in peripheral blood lymphocytes and monocytes in healthy volunteers [20,21]. Therefore, the calprotectin in neutrophils and monocytes is the receptor of RAGE [21].

Calprotectin contained in the cytosol fraction of these cells and released immediately after host-pathogen interaction and cytokine stimulation [22]. Therefore, it is essential to discriminate between intracellular and extracellular interaction partners. It was found in biological fluids in not only infections, but in autoimmune and rheumatic diseases, inflammatory bowel diseases, acute and chronic rejection of renal allografts, obesity, metabolic syndrome, cancer, sepsis, and other acute and chronic inflammatory conditions [19,23-26].

The main biological effect of calprotectin is an endogenous activation of Toll-like receptor 4 (TLR) as innate amplifier of infection, autoimmunity, and cancer that attenuates some extracellular functions, e.g. antimicrobial, cytostatic, and chemotactic activities [27,28]. Therefore, there is evidence that calprotectin activates of NADPH oxidase, induces apoptotic caspase-9 and caspase-3 activation, DNA fragmentation, and membrane phosphatidylserine exposure, increases the activation of nuclear factor-κB (NF-κB) by promoting the nuclear translocation of p65 in target cells [29], subsequently inducing expression of the pro-inflammatory cytokines IL-6, IL-8, TNF-alpha, and COX2 [30]. As result, calprotectin may induce plasma membrane damage via caspase-dependent as well as -independent mechanisms and trigs apoptosis and necrosis [29]. Therefore, calprotectin may induce ATM TLR4/MyD88 and NLRP3 inflammasome-dependent IL-1β production. Finally, IL-1β interacted with the IL-1 receptor on bone marrow myeloid progenitors to stimulate the production of monocytes and neutrophils [30]. All these findings suggest that calprotectin might have proposed for the diagnosis of inflammatory conditions. Despite a lot of number of known functions for calprotectin have proposed, the exactly biological function of this factor remains still not fully understood [31,32].

Calprotectin, Endothelial Dysfunction and Atherosclerosis

Although calprotectin was found as a nonspecific marker for activation of granulocytes, mononuclear phagocytes and immune cells that play a pivotal role in tissue damage, it could link important molecular pathological mechanisms of inflammation contributing to endothelial damage [33,34]. Moreover, calprotectin may specifically released during interaction of activated monocytes with TNF-stimulated endothelial cells [35] and induce a thrombogenic response in human microvascular endothelial cells [36]. These effects realize by increasing the transcription of pro-inflammatory chemokines and adhesion cell molecules and therefore by decreasing the expression of cell junction proteins and molecules involved in monolayer integrity [35,36]. Overall, calprotectin is able to regulate endothelial cell survival via a various signaling mechanism involving membrane-to-nucleus cascade Raf-MEK-ERK via TLR4 and CD11B/CD18 cooperation [37], which play a key role in endothelial dysfunction and atherosclerosis development. Indeed, characteristics of rupture-prone lesions of plaque, inflammatory biomarkers and platelet aggregation correlate well with elevated level of calprotectin [38].

Interestingly that calprotectin may exert a biological effect by binding and affecting various target proteins. There are several additional targets for this heterocomplex protein including p53, a nuclear Dbf2 related kinase, neuromodulin, protein kinase C, the advanced glycation end products (RAGE) receptor. Calprotectin appears to be receptor for RAGE [39], which plays a crucial role during the development of many human diseases (such as diabetes, CV disease), and regulates a number of cell processes of pivotal importance like inflammation, apoptosis, proliferation and autophagy. Accordingly, there is a growing interest of unravelling the intracellular signalling pathways mediating by calprotectin through RAGE [40].

Recent studies suggest that calprotectin correlates positively with platelet aggregation, endothelial cell activation, as well as other biological markers of endothelial dysfunction i.e. serum thromboxane B2 [39,41,42]. Moreover, there is a large of body evidence that elevated calprotectin may predict clinical outcomes in patients with stable coronary artery disease, acute coronary syndrome, acute myocardial dysfunction [43-45].

Croce et al. [46] demonstrated that S100a9-deficiency reduced atherosclerosis in apolipoprotein E-deficient (ApoE-/-) mice through reduced arterial macrophage accumulation. Because of the abundance of calprotectin in myeloid cells compared to non-myeloid cells, myeloid-derived calprotectin was therefore believed to mediate the effects of whole-body calprotectin-deficiency. However, Averill et al. [47] have tested this hypothesis by transplantation of low-density lipoprotein receptor-deficient (Ldlr-/-) mice with bone marrow from S100a9-/- mice or wild type littermate controls followed by feeding a high-fat diet for 20 weeks. The authors reported that bone marrow S100A9-deficiency reduced neither atherosclerotic lesions, arterial wall macrophage, nor neutrophil accumulation. Nevertheless, the increased plasma levels of S100A8/A9 predict cardiovascular CV events in humans, and deletion of these proteins partly protects Apoe(-)(/)(-) mice from atherosclerosis [48]. Taken together, it has been suggested that S100A8/A9 might exert a more important role in non-myeloid cells than previously recognized. Hirata et al. [49] have exhibited that asymptomatic atherosclerosis in diabetics associates strongly with elevated level of calprotectin. Thus, calprotectin may be considered as a very sensitive inflammation-related biological marker of endothelial dysfunction and asymptomatic atherosclerosis, although clear mechanism of calprotectin-induced endothelial dysfunction was not shown and require more investigations.

Calprotectin in Diabetes Mellitus

As an inflammation-associated biomarker, which binds toll-like receptor 4 and associates with the RAGE, calprotectin (S100A8/A9) complex is candidate to be a predictor of diabetes-related complications and CV events in subjects with dysmetabolic diseases, while the results of the clinical studies are limited. Recent clinical studies have shown that increased calprotectin level was associated with type 2 DM, obesity and metabolic syndrome (MetS) [50-53]. Pedersen et al. [13] reported that type 2 DM patients had higher concentrations of plasma calprotectin, which were associated with obesity, MetS status, autonomic neuropathy, peripheral artery disease, and myocardial infarction. However, elevated calprotectin level was not found an independent predictor of CV disease development and progression, as well as manifestation of type 2 DM in general population [54]. Tabur et al. [55] found elevated serum level of calprotectin in individuals with diabetic-induced peripheral neuropathy. Therefore, there was detected a moderate positive correlation between calprotectin levels and high sensitive C-reactive protein and HbA1c. Peng et al. [59] reported that increased calprotectin level is closely associated with atherosclerosis in type 2 DM. Interestingly the increased levels of calprotectin in obesity and obesity-associated type 2 diabetes was found in positive association with low-grading inflammation [57]. However, exposure antidiabetic agent, i.e. pioglitazone, even without changing body mass index might lead to decrease of calprotectin level and improve of endothelial function [58]. There is evidence that insulin resistance and microalbuminuria might be mediated by calprotectin [59,60]. Theoretically, the serum level of calprotectin should decrease in response of therapeutic care as it was found in patients with autoimmune diseases, malignancy, and sepsis. In this context, calprotectin as biomarker of inflammation and endothelial damage with probably predictive value might be considered not only "blinded whiteness" of CV risk, but as a target of DM therapy.

Conclusion

In conclusion, one can propose that calprotectin could identify DM patients at high CV risk. Moreover, calprotectin might be useful for biomarker-guided therapy among DM individuals with high CV risk. This could provide a rationale for monitoring calprotectin in DM patients, although this assumption requires to be discussed and confirmed the results of future clinical studies.

Conflict of Interes

None declared

Acknowledgement

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

References

1. Martín-Timón I, Sevillano-Collantes C, Segura-Galindo A, Javier delCañizo-Gómez F (2014) Type 2 diabetes and cardiovascular disease: Have all risk factors the same strength? World J Diabetes 5: 444-470.
   


2. Barrot-de la Puente J, Mata-Cases M, Franch-Nadal J, Mundet-Tudurì X, Casellas A, et al. (2015) Older type 2 diabetic patients are more likely to achieve glycaemic and cardiovascular risk factors targets than younger patients: analysis of a primary care database. Int J ClinPract 69: 1486-1495.
   


3. Ying-Hua Qiu, Fei-Yan Deng, Min-Jing Li, Shu-Feng Lei (2014) Identification of novel risk genes associated with type 1 diabetes mellitus using a genome-wide gene-based association analysis. J Diabetes Investig 5: 649-656.
   


4. Reinehr T (2013) Type 2 diabetes mellitus in children and adolescents. World J Diabetes 4: 270-281.
   


5. Wei Bao, Frank B. Hu, ShuangRong, Ying Rong, Katherine Bowers, et al. (2013) Predicting Risk of Type 2 Diabetes Mellitus with Genetic Risk Models on the Basis of Established Genome-wide Association Markers: A Systematic Review. Am J Epidemiol 178: 1197-1207.
   


6. Kahn SE, Cooper ME, Del Prato S (2014) Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. Lancet 383: 1068-1083.
   


7. Gao J, Sang M, Zhang X, Zheng T, Pan J, et al. (2015) Miro1-mediated mitochondrial dysfunction under high nutrient stress is linked to NOD-like receptor 3 (NLRP3)-dependent inflammatory responses in rat pancreatic beta cells. Free RadicBiol Med 89:322-332.
   


8. Contreras-Rodríguez A, Gómez-Díaz RA, Tanus-Hajj J, Talavera JO,Mondragón-González R, et al. (2015) Carotid Intima-Media Thickness, Ankle-Arm Index, and Inflammation Profile in Mexican Patients with Early and Late Onset Type 2 Diabetes. Rev Invest Clin 67: 240-249.
   


9. Lodovici M, Bigagli E, Luceri C, Mannucci E, Rotella CM, et al. (2015) Gender-related drug effect on several markers of oxidation stress in diabetes patients with and without complications.Eur J Pharmacol 766: 86-90.
   


10. Sierra Rojas JX, GarcA¬a-SanFrutos M, Horrillo D, Lauzurica N, Oliveros E, et al. (2015) Differential Development of Inflammation and Insulin Resistance in Different Adipose Tissue Depots Along Aging in Wistar Rats: Effects of Caloric Restriction. J Gerontol A BiolSci Med Sci 71: 310-322.
    


11. Lee CH,Changchien CY, Hung YJ (2015) Targeting inflammation in type 2 diabetes by antibody-mediated Tyro-,Axl, Mer receptor activation. J Diabetes Investig 6: 491-494.
    


12. Greenberg AS, Obin MS (2006) Obesity and the role of adipose tissue in inflammation and metabolism. Am J ClinNutr 83: 461S-465S.
    


13. Pedersen L, Nybo M, Poulsen MK, Henriksen JE, Dahl J, et al. (2014) Plasma calprotectin and its association with cardiovascular disease manifestations, obesity and the metabolic syndrome in type 2 diabetes mellitus patients. BMC CardiovascDisord 14:196.
    


14. Kuwabara T, Mori K, Kasahara M, Yokoi H, Imamaki H, et al. (2014) Predictive significance of kidney myeloid-related protein 8 expression in patients with obesity- or type 2 diabetes-associated kidney diseases. PLoS One 9: e88942.
    


15. Nijhuis J, Rensen SS, Slaats Y, van Dielen FM, Buurman WA, et al. (2009) Neutrophil activation in morbid obesity, chronic activation of acute inflammation. Obesity (Silver Spring) 17: 2014-2018.
    


16. Schäfer BW,Heizmann CW (1996) The S100 family of EF-hand calcium-binding proteins: functions and pathology. Trends BiochemSci 21: 134-140.
    


17. Sekimoto R, Kishida K, Nakatsuji H, Nakagawa T, Funahashi T, et al. (2012) High circulating levels of S100A8/A9 complex (calprotectin) in male Japanese with abdominal adiposity and dysregulated expression of S100A8 and S100A9 in adipose tissues of obese mice. BiochemBiophys Res Commun 419: 782-789.
    


18. Sorg C (1992) The calcium binding proteins MRP8 and MRP14 in acute and chronic inflammation. Behring InstMitt : 126-137.
    


19. Goebeler M, Roth J, Burwinkel F, Vollmer E, Bocker W, et al. (1994) Expression and complex formation of S100-like proteins MRP8 and MRP14 by macrophages during renal allograft rejection. Transplantation 58:355-361.
    


20. Kerkhoff C, Klempt M, Sorg C (1998) Novel insights into structure and function of MRP8 (S100A8) and MRP14 (S100A9). Biochim Biophys Acta 1448: 200-211.
    


21. Foell D,Wittkowski H, Vogl T, Roth J (2007) S100 proteins expressed in phagocytes: a novel group of damage-associated molecular pattern molecules. J LeukocBiol 81: 28-37.
    


22. Faust A, Voller T, Busch F, Schafers M, Roth J, et al. (2015) Development and evaluation of a non-peptidic ligand for the molecular imaging of inflammatory processes using S100A9 (MRP14) as a novel target. ChemCommun (Camb) 51: 15637-15640.
    


23. Frosch M, Vogl T, Waldherr R, Sorg C, Sunderkötter C, et al. (2004) Expression of MRP8 and MRP14 by macrophages is a marker for severe forms of glomerulonephritis. J LeukocBiol 75: 198-206.
    


24. Sunderkotter CH, Tomimori-Yamashita J, Nix V, Maeda SM, Sindrilaru A, et al. (2004) High expression of myeloid-related proteins 8 and 14 characterizes an inflammatorily active but ineffective response of macrophages during leprosy. Immunology 111:472-480.
    


25. Ehrchen JM, Sunderkötter C, Foell D, Vogl T, Roth J (2009) The endogenous Toll-like receptor 4 agonist S100A8/S100A9 (calprotectin) as innate amplifier of infection, autoimmunity, and cancer. J LeukocBiol 86: 557-566.
    


26. Decembrino L, De Amici M,Pozzi M, De Silvestri A, Stronati M1 (2015) Serum Calprotectin: A Potential Biomarker for Neonatal Sepsis. J Immunol Res 2015: 147973.
    


27. Catalan V, Gomez-Ambrosi J, Rodriguez A, Ramirez B, Rotellar F, et al. (2011) Increased levels of calprotectin in obesity are related to macrophage content: impact on inflammation and effect of weight loss. Mol Med 17: 1157-1167.
    


28. Rammes A, Roth J, Goebeler M, Klempt M, Hartmann M, et al. (1997) Myeloid-related protein (MRP) 8 and MRP1, calcium-binding proteins of the S100 family, are secreted by activated monocytes via a novel, tubulin-dependent pathway. J BiolChem 272:9496-9502.
    


29. Yui S,Nakatani Y, Mikami M (2003) Calprotectin (S100A8/S100A9), an inflammatory protein complex from neutrophils with a broad apoptosis-inducing activity. Biol Pharm Bull 26: 753-760.
    


30. Nagareddy PR, Kraakman M, Masters SL, Stirzaker RA, Gorman DJ, et al. (2014) Adipose tissue macrophages promote myelopoiesis and monocytosis in obesity. Cell Metab 19:821-835.
    


31. Petrovic D, Milanez T, Kobal J, Bregar D, Potisk KP, et al. (2003) Prothrombotic gene polymorphisms and atherothrombotic cerebral infarction. ActaNeurolScand 108: 109-113.
    


32. Starčević JN, Petrovič D (2013) Carotid intima media-thickness and genes involved in lipid metabolism in diabetic patients using statins--a pathway toward personalized medicine. Cardiovasc Hematol Agents Med Chem 11: 3-8.
    


33. Gebhardt C, Németh J, Angel P, Hess J (2006) S100A8 and S100A9 in inflammation and cancer. Biochem Pharmacol 72: 1622-1631.
    


34. Viemann D, Barczyk K, Vogl T, Fischer U, Sunderkotter C, et al. (2007) MRP8/MRP14 impairs endothelial integrity and induces a caspase-dependent and -independent cell death program. Blood 109: 2453-2460.
    


35. Frosch M, Strey A, Vogl T, Wulffraat NM, Kuis W, et al. (2000) Myeloid-related proteins 8 and 14 are specifically secreted during interaction of phagocytes and activated endothelium and are useful markers for monitoring disease activity in pauciarticular-onset juvenile rheumatoid arthritis. Arthritis Rheum 43: 628-637.
    


36. Viemann D, Strey A, Janning A, Jurk K, Klimmek K, et al. (2005) Myeloid-related proteins 8 and 14 induce a specific inflammatory response in human microvascular endothelial cells. Blood 105: 2955-2962.
    


37. Atallah M, Krispin A, Trahtemberg U, Ben-Hamron S, Grau A, et al. (2012) Constitutive neutrophil apoptosis: regulation by cell concentration via S100 A8/9 and the MEK-ERK pathway. PLoS One 7: e29333.
    


38. Bernlochner I, Steinhubl S, Braun S, Morath T, Jaitner J, et al. (2010) Association between inflammatory biomarkers and platelet aggregation in patients under chronic clopidogrel treatment.ThrombHaemost 104: 1193-1200.
    


39. Larsen SB, Grove EL, Pareek M, Kristensen SD, Hvas AM (2015) Calprotectin and platelet aggregation in patients with stable coronary artery disease. PLoS One 10: e0125992.
    


40. Boyd JH, Kan B, Roberts H, Wang Y, Walley KR (2008) S100A8 and S100A9 mediate endotoxin-induced cardiomyocyte dysfunction via the receptor for advanced glycation end products. Circ Res 102: 1239-1246
    


41. Averill MM, Kerkhoff C, Bornfeldt KE (2012) S100A8 and S100A9 in cardiovascular biology and disease. Arterioscler Thromb Vasc Biol 32: 223-229.
    


42. Altwegg LA, Neidhart M, Hersberger M, Muller S, Eberli FR, et al. (2007) Myeloid-related protein 8/14 complex is released by monocytes and granulocytes at the site of coronary occlusion: a novel, early, and sensitive marker of acute coronary syndromes. Eur Heart J 28: 941-948.
    


43. Healy AM, Pickard MD, Pradhan AD, Wang Y, Chen Z, et al. (2006) Platelet expression profiling and clinical validation of myeloid-related protein-14 as a novel determinant of cardiovascular events. Circulation 113: 2278-2284.
    


44. Ionita MG, Vink A, Dijke IE, Laman JD, Peeters W, et al. (2009) High levels of myeloid-related protein 14 in human atherosclerotic plaques correlate with the characteristics of rupture-prone lesions. ArteriosclerThrombVasc Biol 29: 1220-1227.
    


45. Morrow DA, Wang Y, Croce K, Sakuma M, Sabatine MS, et al. (2008) Myeloid-related protein 8/14 and the risk of cardiovascular death or myocardial infarction after an acute coronary syndrome in the Pravastatin or Atorvastatin Evaluation and Infection Therapy: Thrombolysis in Myocardial Infarction (PROVE IT-TIMI 22) trial. Am Heart J 155: 49-55.
    


46. Croce K, Gao H, Wang Y, Mooroka T, Sakuma M, et al. (2009) Myeloid-related protein-8/14 is critical for the biological response to vascular injury. Circulation 120: 427-436.
    


47. Averill MM, Barnhart S, Becker L, Li X, Heinecke JW, Leboeuf RC, et al. (2011) S100A9 differentially modifies phenotypic states of neutrophils, macrophages, and dendritic cells: implications for atherosclerosis and adipose tissue inflammation. Circulation 123: 1216-1226.
    


48. Averill MM, Kerkhoff C, Bornfeldt KE (2012) S100A8 and S100A9 in cardiovascular biology and disease. Arterioscler Thromb Vasc Biol 32: 223-229.
    


49. Hirata A, Kishida K, Nakatsuji H, Hiuge-Shimizu A, Funahashi T, et al. (2012) High serum S100A8/A9 levels and high cardiovascular complication rate in type 2 diabetics with ultrasonographic low carotid plaque density. Diabetes Res ClinPract 97: 82-90.
    


50. Wilder PT, Lin J, Bair CL, Charpentier TH, Yang D, et al. (2006) Recognition of the tumor suppressor protein p53 and other protein targets by the calcium-binding protein S100B. BiochimBiophysActa 1763:1284-1297.
    


51. Catalán V, Gómez-Ambrosi J, Rodríguez A, Ramírez B, Rotellar F, et al. (2011) Increased levels of calprotectin in obesity are related to macrophage content: impact on inflammation and effect of weight loss. Mol Med 17: 1157-1167.
    


52. Mortensen OH, Nielsen AR, Erikstrup C, Plomgaard P, Fischer CP, et al. (2009) Calprotectin--a novel marker of obesity. PLoS One 4: e7419.
    


53. Ortega FJ, Sabater M, Moreno-Navarrete JM, Pueyo N, Botas P, Delgado E, et al. Serum and urinary concentrations of calprotectin as markers of insulin resistance and type 2 diabetes. Eur J Endocrinol 167: 569-578.
    


54. Kruzliak P, Novák J, Novák M, Fodor GJ4 (2014) Role of calprotectin in cardiometabolic diseases. Cytokine Growth Factor Rev 25: 67-75.
    


55. Tabur S, Korkmaz H, Ozkaya M, Aksoy SN, Akarsu E (2015) Is calprotectin a novel biomarker of neuroinflammation in diabetic periferal neuropathy? Diabetol Metab Syndr 7: 36.
    


56. Peng WH, Jian WX, Li HL, Hou L, Wei YD, et al. (2011) Increased serum myeloid-related protein 8/14 level is associated with atherosclerosis in type 2 diabetic patients. Cardiovasc Diabetol 10: 41.
    


57. Catalán V, Gómez-Ambrosi J, Rodríguez A, Ramírez B, Rotellar F, et al. (2011) Increased levels of calprotectin in obesity are related to macrophage content: impact on inflammation and effect of weight loss. Mol Med 17: 1157-1167.
    


58. Nakatsuji H, Kishida K, Funahashi T, Shimomura I, Senri Study II Group (2012) Three-month treatment with pioglitazone reduces circulating levels of S100A8/A9 (MRP8/14) complex, a biomarker of inflammation, without changes in body mass index, in type 2 diabetics with abdominal obesity. Diabetes Res ClinPract 95: e58-60.
    


59. Ortega FJ,Sabater M, Moreno-Navarrete JM, Pueyo N, Botas P, et al. (2012) Serum and urinary concentrations of calprotectin as markers of insulin resistance and type 2 diabetes. Eur J Endocrinol 167: 569-578.
    


60. Schmaderer C, Kemmner S, Burkhardt K, Heemann U, Baumann M2 (2014) Serum myeloid-related protein 8/14 complex is associated with microalbuminuria in patients with type 2 diabetes. Ther Adv Cardiovasc Dis 8: 80-88.